SkylineDx secures funding for melanoma diagnostic test

Source: Verdict Medical Devices, October 2019

Dutch biotech company SkylineDx has received €20m ($21.9m) funding from Benelux investor Aat van Herk for a skin cancer diagnostic test.

SkylineDx states the investment will finance its market potential of more than $1bn per year, depending on their current progress in the melanoma field.

US-based medical centre Mayo Clinic discovered the melanoma test, which has been optimised and further developed by SkylineDx.

Read the original full article